Stock Events

Stock Events

Theravance Biopharma 

$16.93
20
+$0.00+0% 14:41 Today

Statistics

Day High
16.96
Day Low
16.93
52W High
20.74
52W Low
10.9
Volume
375,058
Avg. Volume
-
Mkt Cap
877.45M
P/E Ratio
7.59
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.31
0.15
0.62
1.08
Expected EPS
0.0725
Actual EPS
N/A

Financials

98.54%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
107.46MRevenue
105.9MNet Income

Analyst Ratings

16.33Average Price Target
The highest estimate is 17.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TBPH. It's not an investment recommendation.
Microsoft
4
MSFT
Tesla
4
TSLA
NVIDIA
4
NVDA
Abbvie
4
ABBV

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, competing in the respiratory and systemic treatment areas similar to Theravance's interests.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Theravance, including respiratory diseases.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie operates in the same biopharmaceutical field, focusing on immunology and chronic diseases, areas where Theravance also has interests.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, particularly in the development of medicines for serious medical conditions, similar to Theravance's mission.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, with a broad range of treatments that could compete with Theravance's products in various therapeutic areas.
Biogen
BIIB
Mkt Cap29.4B
Biogen develops therapies for neurological and neurodegenerative diseases, potentially competing with Theravance's developments in related healthcare sectors.
Lakefront Biotherapeutics NV
GLPG
Mkt Cap1.86B
Galapagos NV specializes in the discovery and development of small molecule medicines with novel modes of action, some of which may compete with Theravance's pipeline.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including for serious medical conditions that overlap with Theravance's focus areas.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca is a global, science-led biopharmaceutical business that competes across several of the same therapeutic areas as Theravance, including respiratory diseases.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. is a global healthcare company that offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing in areas relevant to Theravance's work.

About

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Show more...
CEO
Mr. Rick E. Winningham M.B.A.
Employees
90
Country
Cayman Islands
ISIN
KYG8807B1068

Listings

STU
DE
0TB.STU
XNAS
US
TBPH
F
DE
0TB.F
BOATS
BOATS
TBPH.BOATS

0 Comments

Share your thoughts

FAQ

What is Theravance Biopharma stock price today?▼
The current price of TBPH is $16.93 USD — it has increased by +0% in the past 24 hours. Watch Theravance Biopharma stock price performance more closely on the chart.
What is Theravance Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Theravance Biopharma stocks are traded under the ticker TBPH.
Is Theravance Biopharma stock price growing?▼
TBPH stock has risen by +0.18% compared to the previous week, the month change is a +2.11% rise, over the last year Theravance Biopharma has showed a +50.49% increase.
What is Theravance Biopharma market cap?▼
Today Theravance Biopharma has the market capitalization of 877.45M
When is the next Theravance Biopharma earnings date?▼
Theravance Biopharma is going to release the next earnings report on August 05, 2026.
What were Theravance Biopharma earnings last quarter?▼
TBPH earnings for the last quarter are -0.1 USD per share, whereas the estimation was 0.03 USD resulting in a -457.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Theravance Biopharma revenue for the last year?▼
Theravance Biopharma revenue for the last year amounts to 107.46M USD.
What is Theravance Biopharma net income for the last year?▼
TBPH net income for the last year is 105.9M USD.
How many employees does Theravance Biopharma have?▼
As of July 20, 2026, the company has 90 employees.
In which sector is Theravance Biopharma located?▼
Theravance Biopharma operates in the Health & Wellness sector.
When did Theravance Biopharma complete a stock split?▼
Theravance Biopharma has not had any recent stock splits.
Where is Theravance Biopharma headquartered?▼
Theravance Biopharma is headquartered in South San Francisco, Cayman Islands.